Drugs / TSR-011
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02048488 | Oct 2012 → Sep 2016 | cancer, lymphoma | Tesaro, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TSR-011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02048488 ↗ |
| Action | Inhibit | “TSR-011 is a dual ALK and tropomyosin-related kinase (TRK) inhibitor” PMID 31217479 ↗ Jun 2019 |
| Modality | Small molecule | “TSR-011 is a potent small molecule inhibitor of tyrosine kinases involved in cancer” NCT02048488 ↗ |
| Route | Oral | “Oral TSR-011” NCT02048488 ↗ |